Abemaciclib is an oral CDK4/6 inhibitor, approved by the FDA in 2021, recommended as the preferred option in the treatment of advanced breast cancer. CDK 4/6 inhibitors are the recommended preferred option in the treatment of advanced breast cancer. The EML expert committee recognised its potential for future inclusion and recommended to MPP to explore it for licensing. Abemaciclib has a similar safety profile to ribociclib but with a different dosing regimen, making it an alternative of interest.